India Contract Development and Manufacturing (CDMO) Market - 2024-2033
The India Contract Development and Manufacturing (CDMO) Market was valued at US$ 16.27 Billion in 2024 and is anticipated to reach US$ 31.23 Billion by 2033, at a CAGR of 0.076 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the India Contract Development and Manufacturing (CDMO) Market.
This report delivers a comprehensive overview of the India Contract Development and Manufacturing (CDMO) Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding India Contract Development and Manufacturing (CDMO) Market. The India Contract Development and Manufacturing (CDMO) Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.
India Contract Development and Manufacturing (CDMO) Market Scope:
Key Players
This report delivers a comprehensive overview of the India Contract Development and Manufacturing (CDMO) Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding India Contract Development and Manufacturing (CDMO) Market. The India Contract Development and Manufacturing (CDMO) Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the India Contract Development and Manufacturing (CDMO) Market.
This report delivers a comprehensive overview of the India Contract Development and Manufacturing (CDMO) Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding India Contract Development and Manufacturing (CDMO) Market. The India Contract Development and Manufacturing (CDMO) Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.
India Contract Development and Manufacturing (CDMO) Market Scope:
Key Players
- Aurobindo Pharma Limited
This report delivers a comprehensive overview of the India Contract Development and Manufacturing (CDMO) Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding India Contract Development and Manufacturing (CDMO) Market. The India Contract Development and Manufacturing (CDMO) Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Increase Your Customer Base by 3X using our Partner Identification tool
- Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
- Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
- Prioritize partners by strategic fit rather than general capability.
- Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
- Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
- White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
- Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
- Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
- Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS
3.1. Key Trends and Future Projections
4. SNIPPET BY SERVICE TYPE
4.1. Snippet by Scale of Operation
5. SNIPPET BY END-USER
6. DYNAMICS
6.1. Impacting Factors
6.1.1. Drivers
6.1.1.1. High-Quality Generic Drug Production
6.1.1.2. Growing Vaccine Manufacturing Capabilities
6.1.1.3. XX
6.1.2. Restraints
6.1.2.1. Regulatory Compliance and Complexities
6.1.2.2. Dependence on Raw Material Imports
6.1.2.3. XX
6.1.3. Opportunity
6.1.3.1. High Demand for Complex Drug Formulations
6.1.3.2. XX
6.1.4. Impact Analysis
7. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
7.1. Market Leaders and Pioneers
7.1.1. Emerging Pioneers and Prominent Players
7.1.2. Market Leaders with Established Products
7.2. Latest Developments and Breakthroughs
7.3. India Regulatory and Reimbursement Landscape
7.4. Porter’s Five Forces Analysis
7.5. Supply Chain Analysis
7.6. SWOT Analysis
7.7. Unmet Needs and Gaps
7.8. Recommended Strategies for Market Entry and Expansion
8. CONTRACT DEVELOPMENT AND MANUFACTURING (CDMO) MARKET, BY SERVICE TYPE
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
8.1.2. Market Attractiveness Index, By Service Type
8.2. Contract Development Services*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. Preclinical Development
8.2.4. Formulation Development
8.2.5. Process Development
8.2.6. Clinical Trial Material Production
8.3. Contract Manufacturing Services
8.3.1. API/Bulk Drug Manufacturing
8.3.2. Finished Dosage Form Manufacturing
8.4. Contract Packaging Services
9. CONTRACT DEVELOPMENT AND MANUFACTURING (CDMO) MARKET, BY SCALE OF OPERATION
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Scale of Operation
9.1.2. Market Attractiveness Index, By Scale of Operation
9.2. Preclinical*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Clinical (Phase I, II, III)
9.4. Commercial Manufacturing
10. CONTRACT DEVELOPMENT AND MANUFACTURING (CDMO) MARKET, BY END-USER
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.1.2. Market Attractiveness Index, By End-User
10.2. Pharmaceutical Companies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Biotechnology Companies
10.4. Academic and Research Institutions
11. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
12. COMPETITIVE OVERVIEW AND KEY MARKET PLAYERS
12.1. Market Share Analysis and Positioning Matrix
12.2. Strategic Partnerships, Mergers & Acquisitions
12.3. Key Developments in Product Portfolios and Innovations
12.4. Company Benchmarking
13. COMPANY PROFILES
13.1. Aurobindo Pharma Limited*
13.1.1. Company Overview
13.1.2. Product Portfolio
13.1.2.1. Product Description
13.1.2.2. Product Key Performance Indicators (KPIs)
13.1.2.3. Historic and Forecasted Product Sales
13.1.2.4. Product Sales Volume
14. FINANCIAL OVERVIEW
14.1. Company Revenue
14.1.1. Geographical Revenue Shares
14.1.1.1. Revenue Forecasts
14.1.2. Key Developments
14.1.2.1. Mergers & Acquisitions
14.1.2.2. Key Product Development Activities
14.1.2.3. Regulatory Approvals, etc.
14.1.3. SWOT Analysis
14.2. Dr. Reddy’s Laboratories Ltd.
14.3. Sun Pharmaceutical Industries Ltd.
14.4. Lupin Limited
14.5. Cipla
14.6. NATCO Pharma Limited
14.7. Hetero Labs Limited
14.8. Cadila Pharmaceuticals
14.9. Biocon
14.10. Intas Pharmaceuticals Ltd.LIST NOT EXHAUSTIVE
15. ASSUMPTION AND RESEARCH METHODOLOGY
15.1. Data Collection Methods
15.2. Data Triangulation
15.3. Forecasting Techniques
15.4. Data Verification and Validation
16. APPENDIX
16.1. About Us and Services
16.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS
3.1. Key Trends and Future Projections
4. SNIPPET BY SERVICE TYPE
4.1. Snippet by Scale of Operation
5. SNIPPET BY END-USER
6. DYNAMICS
6.1. Impacting Factors
6.1.1. Drivers
6.1.1.1. High-Quality Generic Drug Production
6.1.1.2. Growing Vaccine Manufacturing Capabilities
6.1.1.3. XX
6.1.2. Restraints
6.1.2.1. Regulatory Compliance and Complexities
6.1.2.2. Dependence on Raw Material Imports
6.1.2.3. XX
6.1.3. Opportunity
6.1.3.1. High Demand for Complex Drug Formulations
6.1.3.2. XX
6.1.4. Impact Analysis
7. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
7.1. Market Leaders and Pioneers
7.1.1. Emerging Pioneers and Prominent Players
7.1.2. Market Leaders with Established Products
7.2. Latest Developments and Breakthroughs
7.3. India Regulatory and Reimbursement Landscape
7.4. Porter’s Five Forces Analysis
7.5. Supply Chain Analysis
7.6. SWOT Analysis
7.7. Unmet Needs and Gaps
7.8. Recommended Strategies for Market Entry and Expansion
8. CONTRACT DEVELOPMENT AND MANUFACTURING (CDMO) MARKET, BY SERVICE TYPE
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
8.1.2. Market Attractiveness Index, By Service Type
8.2. Contract Development Services*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. Preclinical Development
8.2.4. Formulation Development
8.2.5. Process Development
8.2.6. Clinical Trial Material Production
8.3. Contract Manufacturing Services
8.3.1. API/Bulk Drug Manufacturing
8.3.2. Finished Dosage Form Manufacturing
8.4. Contract Packaging Services
9. CONTRACT DEVELOPMENT AND MANUFACTURING (CDMO) MARKET, BY SCALE OF OPERATION
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Scale of Operation
9.1.2. Market Attractiveness Index, By Scale of Operation
9.2. Preclinical*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Clinical (Phase I, II, III)
9.4. Commercial Manufacturing
10. CONTRACT DEVELOPMENT AND MANUFACTURING (CDMO) MARKET, BY END-USER
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.1.2. Market Attractiveness Index, By End-User
10.2. Pharmaceutical Companies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Biotechnology Companies
10.4. Academic and Research Institutions
11. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
12. COMPETITIVE OVERVIEW AND KEY MARKET PLAYERS
12.1. Market Share Analysis and Positioning Matrix
12.2. Strategic Partnerships, Mergers & Acquisitions
12.3. Key Developments in Product Portfolios and Innovations
12.4. Company Benchmarking
13. COMPANY PROFILES
13.1. Aurobindo Pharma Limited*
13.1.1. Company Overview
13.1.2. Product Portfolio
13.1.2.1. Product Description
13.1.2.2. Product Key Performance Indicators (KPIs)
13.1.2.3. Historic and Forecasted Product Sales
13.1.2.4. Product Sales Volume
14. FINANCIAL OVERVIEW
14.1. Company Revenue
14.1.1. Geographical Revenue Shares
14.1.1.1. Revenue Forecasts
14.1.2. Key Developments
14.1.2.1. Mergers & Acquisitions
14.1.2.2. Key Product Development Activities
14.1.2.3. Regulatory Approvals, etc.
14.1.3. SWOT Analysis
14.2. Dr. Reddy’s Laboratories Ltd.
14.3. Sun Pharmaceutical Industries Ltd.
14.4. Lupin Limited
14.5. Cipla
14.6. NATCO Pharma Limited
14.7. Hetero Labs Limited
14.8. Cadila Pharmaceuticals
14.9. Biocon
14.10. Intas Pharmaceuticals Ltd.LIST NOT EXHAUSTIVE
15. ASSUMPTION AND RESEARCH METHODOLOGY
15.1. Data Collection Methods
15.2. Data Triangulation
15.3. Forecasting Techniques
15.4. Data Verification and Validation
16. APPENDIX
16.1. About Us and Services
16.2. Contact Us
